📰 Priority Review News
Page 103 - Priority Review News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Priority Review. Real-time updates on events, politics, business and more.
June 22, 2022
/PRNewswire/ -- The Menarini Group ("Menarini") and Radius Health, Inc. ("Radius") (NASDAQ: RDUS) (collectively, the "Companies") announced that Menarini, with...
June 22, 2022
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patientsPriority Review requested; if accepted, anticipate an 8-month FDA reviewPositive EMERALD study data
June 22, 2022
/PRNewswire/ -- The Menarini Group ("Menarini") and Radius Health, Inc. ("Radius") (NASDAQ: RDUS) (collectively, the "Companies") announced that Menarini, with...
June 20, 2022
Bristol Myers Squibb (NYSE: BMY) today announced that the European Medicines Agency (EMA) has validated its type II variation application for extension of the indication for Breyanzi (lisocabtagene maraleucel) to treat adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL) ...
June 16, 2022
Fast Track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. Some of the significant benefits of FTD include:
June 14, 2022
- Trodelvy is Everest's First Product to Receive Regulatory Approval in China - - Everest Plans to Launch Commercial Sales of Trodelvy in China in Q4 2022 - - Conference call will be held to discuss the approval- SHANGHAI, June 10, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific mar...
June 13, 2022
/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...
June 13, 2022
The FDA panel voted in favor of the approval of beti-cel for patients with beta-thalassemia who require regular red blood cell transfusions.
June 10, 2022
/PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing...
June 10, 2022
FDA panel recommended the approval of eli-cel for the treatment of early active CALD in patients <18 years without a matched sibling donor.